Loading
CTNNA2 (Catenin alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 4 more.
May function as a linker between cadherin adhesion receptors and the cytoskeleton to regulate cell-cell adhesion and differentiation in the nervous system. Required for proper regulation of cortical neuronal migration and neurite growth. It acts as a negative regulator of Arp2/3 complex activity and Arp2/3-mediated actin polymerisation.
IntOGen calls it a driver in 12 cohorts (9 activating, 2 loss-of-function), covering Cholangiocarcinoma, Hepatocellular Carcinoma, Head and Neck Squamous Cell Carcinoma, Lung Adenocarcinoma, Melanoma, Pancreatic Adenocarcinoma and others.
In plain words · CTNNA2 (Catenin alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 4 more.
CTNNA2 (Catenin alpha-2) is a gene that drives cell growth when it is altered. The public catalogues list it as an oncogene driver and a tumour suppressor, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Prostate cancer, Hepatocellular carcinoma, Head and neck squamous cell carcinoma and 4 more.
May function as a linker between cadherin adhesion receptors and the cytoskeleton to regulate cell-cell adhesion and differentiation in the nervous system. Required for proper regulation of cortical neuronal migration and neurite growth.
No product in this corpus aims at CTNNA2 yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
First described 1993. Earliest sequence paper UniProt cites for the protein: Claverie J.-M. et al, Genomics, 1993, "Characterization and chromosomal assignment of a human cDNA encoding a protein related to the murine 102-kDa cadherin-associated protein (alpha-catenin)". Source.
Sources: HGNC HGNC:2510 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P26232 (protein name, function text, keywords and locations (REST API)); IntOGen CTNNA2 (driver in 12 cohorts (Act 9, LoF 2); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
May function as a linker between cadherin adhesion receptors and the cytoskeleton to regulate cell-cell adhesion and differentiation in the nervous system. Required for proper regulation of cortical neuronal migration and neurite growth. It acts as a negative regulator of Arp2/3 complex activity and Arp2/3-mediated actin polymerisation. It thereby suppresses excessive actin branching which would impair neurite growth and stability. Regulates morphological plasticity of synapses and cerebellar and hippocampal lamination during development. Functions in the control of startle modulation. Location: Cell membrane; Cytoplasm; Cytoplasm, cytoskeleton; Cell junction, adherens junction (UniProt). Locus 2p12 (HGNC).
Query for this target: (TITLE:"CTNNA2" OR ABSTRACT:"CTNNA2" OR TITLE:"catenin alpha 2" OR ABSTRACT:"catenin alpha 2" OR TITLE:"Catenin alpha-2" OR ABSTRACT:"Catenin alpha-2" OR TITLE:"CAP-R" OR ABSTRACT:"CAP-R" OR TITLE:"CT114" OR ABSTRACT:"CT114") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about CTNNA2, not a curated reading list.